FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours ner resnonse:	0.5						

_	Check this box if no longer subject to Section 16.
-1	Form 4 or Form 5 obligations may continue. See
_	Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MORRISSEY MICHAEL					2. Issuer Name and Ticker or Trading Symbol EXELIXIS, INC. [EXEL]									onship of Reporti all applicable) Director		,	10% Ow	
(Last) C/O EXELIXIS, INC. 1851 HARBOR BAY	(First)	•	ddle)		3. Date of Earliest Transaction (Month/Day/Year) 08/03/2022								X	Officer (give title below) Other (specify below) President and CEO				
(Street) ALAMEDA (City)	CA (State)	94 (Zi _I	502	4	4. If Amendment, Date of Original Filed (Month/Day/Year)									dual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
			Table I -	Non-D	erivative	Securi	ities Acc	quired,	Disp	osed of	, or Be	neficially	Owned					
District of Security (many s)				Date	Transaction ate 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Dispos (D) (Instr. 3, 4 and 5)				isposed Of	5. Amount of Securiti Beneficially Owned Following Reported Transaction(s) (Instr.		Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
						(Month/Day/Tear)		Code	٧	Amount		(A) or (D)	Price	and 4)				(Instr. 4)
Common Stock ⁽¹⁾				08/0	3/2022 ⁽²⁾		Α		94,002(3)		Α	\$0	493,273(4)		D			
Common Stock				08/	08/03/2022			F		23,304(5)		D	\$21.49	469,969		D		
Common Stock													1,196,316		I		By Trust ⁽⁶⁾	
Common Stock													17,7280	17,728 ⁽⁷⁾		I	By 401(k)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (In	str. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea		Underlying Derivative Sec			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following	ve es ially	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercise		Expiration Date	Title		Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		(IIIəu. 4)	
Explanation of Responses	:																	

- 1. Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc.
- 2. On October 22, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exclixis, Inc. 2017 Equity Incentive Plan covering 188,005 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement of certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.
- 3. On August 3, 2022, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on August 15, 2023, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024.
- 4. Includes 387,656 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units
- 5. Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on August 3, 2022.
- 6. Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended
- 7. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of August 3, 2022.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Nina Ayer, Attorney in Fact ** Signature of Reporting Person

08/05/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints, Christopher J. Senner, Jeffery J. Hessekiel and Nina Ayer of
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoeve:
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Schedule
In Witness Whereof, the undersigned has caused this Power of Attorney to be executed as of 5/27/2022.

Michael M. Morrissey Print Name

/s/ Michael M. Morrissey Signature